Chronic pancreatitis (CP) is characterised by recurrent abdominal pain. The pathological hallmarks of CP is pancreatic stellate cell activation that results in persistent inflammation and progressive fibrosis. It has been shown in various clinical and experimental studies that with disease progression there could be pancreatic neural inflammation, spinal sensitization and eventually alteration in the pain modulating architecture within the brain (widespread sensitization). These events result in different types of pain (nociceptive and neuropathic) in patients with CP, which may dynamically change during disease progression.

Since the treatment for different mechanisms are unique, it becomes important to identify the predominant type of pain. Recently, pancreatic quantitative sensory testing (P-QST) has emerged as a valuable tool to identify different types of sensitization. This facility is currently available only in select centers and is being conducted under research protocols.

In this study, we propose to: 1. evaluate the patterns of pain in CP and the triggers; 2. identify clinical surrogates of sensitization, i.e. neuropathic pain.

The ultimate goal is to apply the best possible pain management strategy based on our research findings for patients with CP in a personalised manner.

Inclusion Criteria:

• At least 3 years of disease (chronic pancreatitis)
• Both genders
• Able to provide informed consent

Exclusion Criteria:

• Acute exacerbation of chronic pancreatitis
• Moderate to severe abdominal pain at the time of screening
• Pancreatic cancer or other malignancies
• Use of antidepressants, narcotics, and neuromodulators

Patients with documented CP will be screened for enrolment criteria. Those fulfilling criteria will be enrolled after written informed consent.